Follicular Lymphomas Can Be Induced to Present Alloantigen Efficiently: a Conceptual Model to Improve Their Tumor Immunogenicity

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1995 Aug 29

PMID 7545296

Citations 55

Authors

J L Schultze

A A Cardoso

G J Freeman

M J Seamon

J Daley

G S Pinkus

J G Gribben

L M Nadler

Affiliations

Soon will be listed here.

Abstract

In the tumor-bearing host, T cells invariably fail to induce a clinically significant antitumor immune response. Although model systems support the existence of tumor peptide antigens, the molecular interactions critical for antigen presentation by the tumor cell remain unresolved. Here, we demonstrate that human follicular lymphoma cells are highly inefficient at presenting alloantigen despite their strong expression of major histocompatibility complex and low-to-intermediate expression of some adhesion and B7 costimulatory molecules. Activation of follicular lymphoma cells via CD40 induces or up-regulates both adhesion and B7 costimulatory molecules essential to repair this defect. More importantly, once primed, alloreactive T cells efficiently recognize unstimulated follicular lymphoma cells. Thus, correction of defective tumor immunity requires not only expression of major histocompatibility complex but also sufficient expression of multiple adhesion and costimulatory molecules.

Citing Articles

Candidate tumor-specific CD8 T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis.

Sugita Y, Muraoka D, Demachi-Okamura A, Komuro H, Masago K, Sasaki E Oncoimmunology. 2024; 13(1):2371556.

PMID: 38952674 PMC: 11216099. DOI: 10.1080/2162402X.2024.2371556.

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.

Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M Cell Commun Signal. 2023; 21(1):252.

PMID: 37735675 PMC: 10512514. DOI: 10.1186/s12964-023-01282-2.

Single-cell sequencing on CD8 TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer.

Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K J Immunother Cancer. 2023; 11(8).

PMID: 37544663 PMC: 10407349. DOI: 10.1136/jitc-2023-007180.

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.

Mota I, Patrucco E, Mastini C, Mahadevan N, Thai T, Bergaggio E Nat Cancer. 2023; 4(7):1016-1035.

PMID: 37430060 DOI: 10.1038/s43018-023-00591-2.

Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy.

Zhang B, Choi I Clin Cancer Res. 2022; 28(20):4363-4369.

PMID: 35686929 PMC: 9714122. DOI: 10.1158/1078-0432.CCR-21-3408.

References

Matulonis U, Dosiou C, Lamont C, Freeman G, Mauch P, Nadler L . Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995; 85(9):2507-15. View

Urashima M, Chauhan D, Uchiyama H, Freeman G, Anderson K . CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995; 85(7):1903-12. View

Dranoff G, Mulligan R . Gene transfer as cancer therapy. Adv Immunol. 1995; 58:417-54. DOI: 10.1016/s0065-2776(08)60624-0. View

STEIN H, Gerdes J, Mason D . The normal and malignant germinal centre. Clin Haematol. 1982; 11(3):531-59. View

Freedman A, Boyd A, Berrebi A, Horowitz J, Levy D, Rosen K . Expression of B cell activation antigens on normal and malignant B cells. Leukemia. 1987; 1(1):9-15. View

Marlin S, Springer T . Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987; 51(5):813-9. DOI: 10.1016/0092-8674(87)90104-8. View

van Seventer G, Shimizu Y, Horgan K, Shaw S . The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990; 144(12):4579-86. View

Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J . Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173(3):721-30. PMC: 2118836. DOI: 10.1084/jem.173.3.721. View

Gribben J, Freedman A, Neuberg D, Roy D, BLAKE K, Woo S . Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991; 325(22):1525-33. DOI: 10.1056/NEJM199111283252201. View

10.

Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

11.

Townsend S, Allison J . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993; 259(5093):368-70. DOI: 10.1126/science.7678351. View

12.

Ranheim E, Kipps T . Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993; 177(4):925-35. PMC: 2190967. DOI: 10.1084/jem.177.4.925. View

13.

Tao M, Levy R . Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature. 1993; 362(6422):755-8. DOI: 10.1038/362755a0. View

14.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

15.

Pardoll D . Cancer vaccines. Immunol Today. 1993; 14(6):310-6. DOI: 10.1016/0167-5699(93)90051-L. View

16.

Boussiotis V, Freeman G, Gray G, Gribben J, Nadler L . B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993; 178(5):1753-63. PMC: 2191250. DOI: 10.1084/jem.178.5.1753. View

17.

Freeman G, Gribben J, Boussiotis V, Ng J, Restivo Jr V, Lombard L . Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993; 262(5135):909-11. DOI: 10.1126/science.7694363. View

18.

Pardoll D . New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol. 1993; 5(5):719-25. DOI: 10.1016/0952-7915(93)90127-e. View

19.

Boussiotis V, Freeman G, Gribben J, Daley J, Gray G, Nadler L . Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A. 1993; 90(23):11059-63. PMC: 47921. DOI: 10.1073/pnas.90.23.11059. View

20.

Chen L, Linsley P, Hellstrom K . Costimulation of T cells for tumor immunity. Immunol Today. 1993; 14(10):483-6. DOI: 10.1016/0167-5699(93)90262-J. View